U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

As part of Pluri's previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has been exercised to fund manufacturing, in-vitro, and in-vivo studies of Pluri's cell therapy PLX-R18 is designed to be a first in class, effective treatment for ionizing radiation injuries that could be anticipated in the wake of a large-scale nuclear incident Work during the contract period is expected to make fur ...